Manufacturer's investigation conclusion: a specific cause for the reported events, as well as a direct correlation to heartmate (hm) 3 left ventricular assist system (lvas), serial number (b)(4), could not conclusively be determined through this evaluation.The controller event and periodic log files collectively contained data from (b)(6) 2021 through (b)(6) 2022, per the timestamps.No notable pump-related events were captured, and the pump appeared to function as intended at the set speed.Multiple attempts were made to obtain additional information from the customer regarding the event; however, no additional information was provided.The patient remains ongoing on hm3 lvas, serial number (b)(4), and no further events have been reported at this time.The heartmate 3 lvas ifu, rev.C, is currently available.Section 1 of the ifu, ¿introduction¿, lists potential adverse events, including multiple types of organ failure and dysfunction (respiratory failure, right heart failure, renal failure, and hepatic dysfunction), that may be associated with the use of the heartmate 3 left ventricular assist system.The relevant sections of the device history records for (b)(4) were reviewed and showed no deviations from manufacturing or quality assurance specifications.The implant kit was shipped on 21-apr-2021.No further information was provided.The manufacturer is closing the file on this event.
|
It was reported that the patient was seen in the clinic on (b)(6) 2022 with ongoing fatigue, dyspnea, bloating, and elevated n-terminal (nt)-pro hormone bnp (nt-probnp).Worsening renal insufficiency and hepatic dysfunction were also noted.Ventricular assist device (vad) interrogations had been benign and no alarms were noted.Log file review captured multiple pulsatility index (pi) events with no other unusual events observed.It was planned to perform a right heart catheterization (rhc) and ramp testing.
|